Sign in

Pharma AI Evidence Readiness

Pharma AI Evidence Readiness evaluates whether AI-driven models and analyses are credible, compliant, and suitable for use in FDA-regulated drug development and regulatory submissions. It reviews model design, data provenance, validation rigor, and alignment with evolving guidance across discovery, clinical trials, manufacturing, and evidence synthesis. This helps pharma and biotech organizations de‑risk AI adoption, accelerate approval-ready evidence packages, and increase regulator confidence in AI-enabled decision making.

The Problem

“Biotech and pharma R&D is slow, expensive, and risky.”

The Shift

Before AI~85% Manual

Human Does

  • •Collect model documentation, datasets, validation reports, and supporting evidence from across R&D functions
  • •Review model design, data provenance, and validation rigor against internal standards and regulatory expectations
  • •Manually reconcile gaps, inconsistencies, and missing traceability across discovery, clinical, manufacturing, and evidence packages
  • •Decide whether AI outputs are credible and suitable for regulated use or submission support

Automation

  • •No consistent AI support in the legacy workflow
  • •Limited use of basic search and document retrieval
  • •Occasional spreadsheet-based tracking of review items
With AI~75% Automated

Human Does

  • •Set evidence-readiness criteria, review thresholds, and acceptable use boundaries for each regulated context
  • •Review flagged gaps, high-risk findings, and ambiguous evidence before release or submission use
  • •Approve remediation priorities, final readiness determinations, and submission inclusion decisions

AI Handles

  • •Aggregate and organize model evidence, source documentation, and validation artifacts into a traceable review package
  • •Assess completeness, provenance, validation coverage, and alignment to applicable regulatory guidance
  • •Flag missing documentation, unsupported claims, weak validation, and cross-functional inconsistencies for review
  • •Generate standardized readiness summaries, risk rankings, and remediation checklists for each use case

Operating Intelligence

How Pharma AI Evidence Readiness runs once it is live

Humans set constraints. AI generates options.

Humans choose what moves forward.

Selections improve future generation quality.

Confidence84%
ArchetypeGenerate & Evaluate
Shape6-step branching
Human gates2
Autonomy
50%AI controls 3 of 6 steps

Who is in control at each step

Each column marks the operating owner for that step. AI-led actions sit above the divider, human decisions and feedback loops sit below it.

Loop shapebranching

Step 1

Define Constraints

Step 2

Generate

Step 3

Evaluate

Step 4

Select & Refine

Step 5

Deliver

Step 6

Feedback

AI lead

Autonomous execution

2AI
3AI
5AI
gate
gate

Human lead

Approval, override, feedback

1Human
4Human
6↺ Loop
AI-led step
Human-controlled step
Feedback loop
TL;DR

Humans define the constraints. AI generates and evaluates options. Humans select what ships. Outcomes train the next generation cycle.

The Loop

6 steps

1 operating angles mapped

Operational Depth

Technologies

Technologies commonly used in Pharma AI Evidence Readiness implementations:

Predictive analyticsOther
4 mentions
Real-time monitoring systemsOther
4 mentions
Clinical trial optimization softwareOther
3 mentions
Patient screening workflowsOther
3 mentions
TransferNet-PDOOther
2 mentions

Key Players

Companies actively working on Pharma AI Evidence Readiness solutions:

TempusAI drug discovery firmsRecursion Pharmaceuticals

Real-World Use Cases

AI-assisted evidence extraction for FDA Q13 continuous manufacturing guidance

An AI system reads the FDA’s Q13 guidance and pulls out the important regulatory facts teams need when designing or documenting continuous manufacturing processes.

document intelligence and evidence extractionproposed workflow grounded in a published fda guidance document; the source confirms the regulatory content to extract, not a live ai deployment.
10.0

AI for clinical trial optimization and patient screening

AI helps match the right patients to trials, watch trial data as it comes in, and improve how studies are designed.

optimization and decision supportfast-rising; identified as the fastest-growing application segment.
10.0

AI credibility assessment for drug regulatory submissions

Drug companies may use AI to generate evidence for FDA decisions, but they need a structured way to show the AI can be trusted for that exact job.

risk scoring and evidence-based validationproposed regulatory workflow; draft guidance issued, not for implementation.
10.0

AI for post-authorisation monitoring and use of medicines

Use AI after a medicine is approved to help monitor information and support its ongoing safe use.

monitoring, signal detection, and decision supportproposed lifecycle use case in regulatory guidance; no specific deployed system is named in the source.
10.0

AI-driven production oversight across the drug product life cycle

AI can act like a smart assistant that reviews lots of production-related information and flags patterns humans might miss across development and manufacturing.

decision support and cross-domain pattern recognitionproposed and actively emerging; fda governance structures indicate real operational momentum, but broad standardized deployment is still forming.
10.0
+6 more use cases(sign up to see all)

Free access to this report